Workflow
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Arrowhead PharmaceuticalsArrowhead Pharmaceuticals(US:ARWR) Businesswire·2025-09-10 11:30

临床进展 - 公司已提交ARO-MAPT的1/2a期临床试验监管审批申请 [1] - ARO-MAPT为研究性RNA干扰疗法 靶向治疗tau蛋白病包括阿尔茨海默病 [1] - 阿尔茨海默病是以认知功能衰退为特征的进行性神经退行性疾病 属于最常见痴呆病因 [1]